Your browser doesn't support javascript.
loading
Confirmation of specificity of reactivity in a solid phase ELISA for the detection of hepatitis E viral antigen improves utility of the assay.
Ankcorn, M J; Ijaz, S; Haywood, B; Neuberger, J; Elsharkawy, A M; Maggs, J; Tedder, R S.
  • Ankcorn MJ; Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England, London, UK; Transfusion Microbiology, National Health Service Blood and Transplant, London, UK. Electronic address: Michael.Ankcorn@phe.gov.uk.
  • Ijaz S; Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England, London, UK. Electronic address: Samreen.Ijaz@phe.gov.uk.
  • Haywood B; Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England, London, UK. Electronic address: Becky.Haywood@phe.gov.uk.
  • Neuberger J; The Liver Unit, University Hospitals Birmingham, Birmingham, UK. Electronic address: James.Neuberger@uhb.nhs.uk.
  • Elsharkawy AM; The Liver Unit, University Hospitals Birmingham, Birmingham, UK. Electronic address: Ahmed.ElSharkawy@uhb.nhs.uk.
  • Maggs J; Gastrointestinal and Liver Services, Buckinghamshire Healthcare NHS Trust, Buckinghamshire, UK. Electronic address: jamesmaggs@nhs.net.
  • Tedder RS; Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England, London, UK; Transfusion Microbiology, National Health Service Blood and Transplant, London, UK; University College London, Gower Street, London, UK. Electronic address: Richard.Tedder@phe.gov.uk.
J Virol Methods ; 252: 42-48, 2018 02.
Article en En | MEDLINE | ID: mdl-29158182
ABSTRACT
Genotype 3 hepatitis E virus (HEV) can lead to persistent infections in immunocompromised hosts. A recently available commercial assay for the detection of HEV antigen (HEV-Ag ELISA, Wantai diagnostics) may enable the study of HEV-Ag dynamics in such persistent infections, however currently there is no confirmatory test available. We generated a putative neutralising reagent from a pool of four convalescent blood donor samples and explored neutralising activity against HEV antigens from clinical samples, HEV tissue-culture and virus-like particles. Using this neutralisation method we were able to differentiate true reactivity from non-specific reactivity in plasma, stool and urine samples. This could also facilitate the introduction of HEV-Ag detection as a screening assay or the study of HEV-Ag in different body fluids.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ensayo de Inmunoadsorción Enzimática / Hepatitis E / Antígenos e de la Hepatitis B Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ensayo de Inmunoadsorción Enzimática / Hepatitis E / Antígenos e de la Hepatitis B Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2018 Tipo del documento: Article